{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:03:28Z","timestamp":1792782208507,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":3146,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MJS-S","award":["FS\/14\/27\/30752"],"award-info":[{"award-number":["FS\/14\/27\/30752"]}]},{"name":"DPF","award":["FS\/010\/038"],"award-info":[{"award-number":["FS\/010\/038"]}]},{"name":"GDC","award":["FS\/12\/12\/29294"],"award-info":[{"award-number":["FS\/12\/12\/29294"]}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The prescription of optimal medical therapy for heart failure is often delayed despite compelling evidence of a reduction in mortality. We calculated the absolute risk resulting from delayed prescription of therapy. For comparison, we established the threshold applied by clinicians when discussing the risk for death associated with an intervention, and the threshold used in official patient information leaflets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We undertook a meta-analysis of randomized controlled trials to calculate the excess mortality caused by deferral of medical therapy for 1\u2009year. Risk ratios for angiotensin-converting enzyme inhibitors, beta-blockers and aldosterone antagonists were 0.80, 0.73 and 0.77, respectively. In patients who might achieve a 1-year survival rate of 90% if treated, a 1-year deferral of treatment reduced survival to 78% (i.e. an annual absolute increase in mortality of 12 in 100 patients). This corresponds to an additional absolute mortality risk per month of 1%. A survey of clinicians carried out to establish the risk threshold at which they would obtain written consent showed the majority (85%) sought written consent for interventions associated with a 12-fold lower mortality risk: one in 100 patients. A systematic review of UK patient information leaflets to establish the magnitude of risk considered sufficient to be stated explicitly showed that leaflets begin to mention death at a \u223c18\u2009000-fold lower mortality risk of just 0.0007 in 100 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deferring heart failure treatment for 1\u2009year carries far greater risk than the level at which most doctors seek written consent, and 18\u2009000 times more risk than the level at which patient information leaflets begin to mention death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.838","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T01:16:24Z","timestamp":1496970984000},"page":"1401-1409","source":"Crossref","is-referenced-by-count":48,"title":["The Mortality Risk of Deferring Optimal Medical Therapy in Heart Failure: A Systematic Comparison Against Norms for Surgical Consent and Patient Information Leaflets"],"prefix":"10.1093","volume":"19","author":[{"given":"Sameer","family":"Zaman","sequence":"first","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman S.","family":"Zaman","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Scholtes","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Shun-Shin","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Plymen","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel P.","family":"Francis","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham D.","family":"Cole","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"2026011721202533500_ejhf838-bib-0001","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0002","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0003","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/fampra\/cml036","article-title":"\u2018Can I come off the tablets now?\u2019 A qualitative analysis of heart failure patients' understanding of their medication","volume":"23","author":"Field","year":"2006","journal-title":"Fam Pract"},{"key":"2026011721202533500_ejhf838-bib-0004","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jchf.2014.04.012","article-title":"\u2018Triple therapy\u2019 of heart failure with ACE inhibitor, beta-blocker and aldosterone antagonist may triple survival time: shouldn't we tell patients?","volume":"2","author":"Cole","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0005","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","article-title":"Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information","volume":"168","author":"Barron","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721202533500_ejhf838-bib-0006","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"2026011721202533500_ejhf838-bib-0007","doi-asserted-by":"crossref","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"key":"2026011721202533500_ejhf838-bib-0008","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"2026011721202533500_ejhf838-bib-0009","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03.36","article-title":"Conducting meta-analyses in R with the metafor package","author":"Viechtbauer","year":"2010","journal-title":"J Stat Soft"},{"key":"2026011721202533500_ejhf838-bib-0010","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-98141-3","volume-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2009"},{"key":"2026011721202533500_ejhf838-bib-0011","author":"Donkor","year":"2015"},{"key":"2026011721202533500_ejhf838-bib-0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.108.812172","article-title":"Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people","volume":"119","author":"Jhund","year":"2009","journal-title":"Circulation"},{"key":"2026011721202533500_ejhf838-bib-0013","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ehj.2003.12.012","article-title":"Decreasing one-year mortality and hospitalization rates for heart failure in Sweden","volume":"25","author":"Schaufelberger","year":"2004","journal-title":"Eur Heart J"},{"key":"2026011721202533500_ejhf838-bib-0014","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCHEARTFAILURE.112.000161","article-title":"Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry","volume":"6","author":"Tavazzi","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721202533500_ejhf838-bib-0017","volume-title":"Health A\u2013Z \u2013 Conditions and treatments","author":"NHS Choices"},{"key":"2026011721202533500_ejhf838-bib-0018","doi-asserted-by":"crossref","first-page":"g1606","DOI":"10.1136\/bmj.g1606","article-title":"Delayed antibiotic prescribing strategies for respiratory tract infections in primary care: pragmatic, factorial, randomized controlled trial","volume":"348","author":"Little","year":"2014","journal-title":"BMJ"},{"key":"2026011721202533500_ejhf838-bib-0019","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721202533500_ejhf838-bib-0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/eurjhf\/hfq214","article-title":"Comparable or STAR-heartlingly different left ventricular ejection fraction at baseline?","volume":"13","author":"Cole","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0021","doi-asserted-by":"crossref","first-page":"h4662","DOI":"10.1136\/bmj.h4662","article-title":"Trials are best, ignore the rest: safety and efficacy of digoxin","volume":"351","author":"Cole","year":"2015","journal-title":"BMJ"},{"key":"2026011721202533500_ejhf838-bib-0022","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0023","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ejhf.623","article-title":"Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril\/valsartan in the USA","volume":"18","author":"Packer","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721202533500_ejhf838-bib-0024","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual economic global economic burden of heart failure","volume":"171","author":"Cook","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/11\/1401\/66327599\/eurjhf_19_11_1401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/11\/1401\/66327599\/eurjhf_19_11_1401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:22:40Z","timestamp":1768702960000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/11\/1401\/8418486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,6,8]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.838","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,6,8]]}}}